Furthermore, the upregulation of ERBB4 in metastatic ES patients was closely associated with poor survival in ES patients, and ERBB4-mediated activation of the PI3K/AKT/FAK/RAC1 pathway promoted the metastatic capacity of ES cells (Mendoza-Naranjo et al., 2013). The gene discussed is PTK2; the disease is Ewing sarcoma.